Theravance Biopharma, Inc.
TBPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -23.7% | 70.2% | -17.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.4% | 60% | 25.6% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9.5% | -8.8% | -91.1% | -40.5% |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 18.1% | 209.3% | -88.2% | -82.8% |
| EPS Diluted | 0.07 | 1.08 | -0.27 | -0.31 |
| % Growth | -93.5% | 500% | 12.9% | – |
| Operating Cash Flow | -$0 | $0 | $0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | $0 | $0 | -$0 |